Synapse - Tiffany Traina

Results (250)

Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

Meeting Abstract

Traina, T. A.; Rugo, H.; Caravelli, J.; Yeh, B.; Panageas, K.; Bruckner, J.; Norton, L.; Park, J.; Hudis, C.; Dickler, M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B)

Meeting Abstract

Rugo, H. S.; Dickler, M. N.; Traina, T. A.; Scott, J. H.; Moore, D. H.; Bruckner, J.; Hudis, C.; Park, J. W.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer

Journal Article

Traina, T. A.; Norton, L.; Drucker, K.; Singh, B.
The Oncologist (2006)

Fulltext@MSK | Save

Hematology and oncology pearls

Book Whole

Mosby Elsevier (2005)

Fulltext@MSK | Save

Optimizing chemotherapeutic dose-schedule (CDS) by Norton-Simon modeling: Capecitabine (Xeloda (R) = X)

Meeting Abstract

Norton, L.; Dugan, U.; Young, D.; Farrell, C.; Tanaka, Y.; Theodoulou, M.; Traina, T.; Hudis, C.
Cancer Research (2005)

Fulltext@MSK | Save

A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer

Meeting Abstract

Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Park, J.; Hudis, C.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)